Will the FDA approve any psychedelic substance for medical use this year?
3.0 Pkt. (24h)Health & MedicineOne-Off3Mon
KalshiVerfügbarkeit prüfenKYC erforderlich2% GebührVerifizierte AuflösungsdatenOrdentlich kalibriertAktuelle implizite Wahrscheinlichkeit
Nein 71%
Marktqualitat
64 / 100
Mittlere Qualität24h-Volumen
62,6 €
Liquidität
77.034,7 €
Hohe LiquiditätGeld / Brief
29.0% / 33.0%
Spread
4.0 pt
Mittlerer SpreadMarktdaten
Aktualisiert vor 6 Minuten
17. Juli 25, 14:00 UTC1. Jan. 27, 04:59 UTC
Trends
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
Will the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsWill the FDA approve MDMA for PTSD?
KalshiWhen will the FDA approve Compass Pathways' COMP360 Psilocybin?
Kalshi[ACX 2026] Will the FDA approve a psilocybin treatment during 2026?
Manifold MarketsWill the FDA approve a psilocybin treatment during 2026?
FutuurWill the FDA approve intismeran autogene (V940/mRNA-4157)?
KalshiRegeln
If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.
- Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca.
- Important information: For purposes of this Contract:
- The listed substances are illustrative, not exhaustive.
- Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion.
- "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product.
Offene Märkte
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No97%
- Yes3%
- Gesamtvolumen
- 15,6 Mio. €
- 24h-Volumen
- 20.404 €
POLYMARKETNew pandemic in 2026?
- No94.1%
- Yes5.9%
- Gesamtvolumen
- 918.998,9 €
- 24h-Volumen
- 4170,6 €
KALSHIMedtronic cardiovascular growth in Q2
- Above 8%92%
- Above 9%81%
- Above 11.5%53%
+6 weitere Ergebnisse
- Gesamtvolumen
- 2605,3 €
- 24h-Volumen
- 2605,3 €
POLYMARKETMeasles cases in U.S. in 2026?
- ↑3.5k+0.1pt100%
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
+9 weitere Ergebnisse
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000+3.0pt61%
+2 weitere Ergebnisse
- Gesamtvolumen
- 866.739 €
- 24h-Volumen
- 1697 €
KALSHIPandemic in 2026?
- No95%
- Yes5%
- Gesamtvolumen
- 611.782,3 €
- 24h-Volumen
- 1101 €
- When will Beam Therapeutics submit a BLA for Risto-cel?
- Which countries will report an Ebola disease case before October?
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- Heidi Overton confirmed as FDA Commissioner by which date?
- Will the FDA approve retatrutide?
- Ebola pandemic in 2026?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- Measles cases in U.S. by September 30?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- FDA approves Retatrutide this year?
Häufige Fragen
- Wie stehen die aktuellen Quoten für Will the FDA approve any psychedelic substance for medical use this year??
- Kalshi bewertet No mit 71% (Stand: 10. September 2026).
- Wann wird Will the FDA approve any psychedelic substance for medical use this year? entschieden?
- Will the FDA approve any psychedelic substance for medical use this year? soll am 1. Januar 2027 entschieden werden.
- Wie wird Will the FDA approve any psychedelic substance for medical use this year? abgerechnet?
- Kalshi rechnet diesen Markt wie folgt ab: If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.